Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Crispr Therapeutics AG

Current price
55.05 USD -1.11 USD (-1.98%)
Last closed 56.16 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 143 916 032 USD
Yield for 12 month +10.34 %
21.11.2021 - 28.11.2021

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Address: Baarerstrasse 14, Zug, Switzerland, 6300

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

85.83 USD

P/E ratio

Dividend Yield

Current Year

+370 000 000 USD

Last Year

+436 000 USD

Current Quarter

+200 000 000 USD

Last Quarter

Current Year

+239 750 000 USD

Last Year

-109 814 000 USD

Current Quarter

+180 000 000 USD

Last Quarter

-23 422 000 USD

Key Figures CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -202 700 992 USD
Operating Margin TTM 34.58 %
PE Ratio
Return On Assets TTM -6.22 %
PEG Ratio -0.2142
Return On Equity TTM -8.17 %
Wall Street Target Price 85.83 USD
Revenue TTM 371 206 016 USD
Book Value 23.52 USD
Revenue Per Share TTM 4.69 USD
Dividend Share
Quarterly Revenue Growth YOY 3353333.2 %
Dividend Yield
Gross Profit TTM -570 697 000 USD
Earnings Share -1.94 USD
Diluted Eps TTM -1.94 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -41.38 %

Dividend Analytics CRSP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 333333:100
Payout Ratio
Last Split Date 19.07.2016
Dividend Date

Stock Valuation CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 23.3645
Enterprise Value Revenue 9.9859
Price Sales TTM 13.8733
Enterprise Value EBITDA -18.2278
Price Book MRQ 2.7352

Financials CRSP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRSP

For 52 weeks

37.55 USD 91.1 USD
50 Day MA 73.59 USD
Shares Short Prior Month 14 724 239
200 Day MA 59.49 USD
Short Ratio 10.24
Shares Short 14 757 233
Short Percent 18.63 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics